XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...
The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...
GlobalData on MSN8h
Palatin’s UC therapy prompts clinical remission in a third of patientsA third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...
AnHorn Medicines Announces First Subject Dosed in AH-001 Phase I Clinical Trial in the United States
AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class ...
The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.
Clinical Trials Arena on MSN1d
Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’sAcumen Pharmaceuticals has concluded enrolment for the Phase II ALTITUDE-AD trial of sabirnetug for treating patients with ...
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS Center.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...
The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with ...
First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated ...
A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback